​

Acrivon Therapeutics (ACRV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ACRV Stock Forecast

Acrivon Therapeutics (ACRV) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $21.83, with a high of $30.00 and a low of $17.00. This represents a 733.21% increase from the last price of $2.62.

- $6 $12 $18 $24 $30 High: $30 Avg: $21.83 Low: $17 Last Closed Price: $2.62

ACRV Stock Rating

Acrivon Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 9 Strong Sell Sell Hold Buy Strong Buy

ACRV Price Target Upside V Benchmarks

TypeNameUpside
StockAcrivon Therapeutics733.21%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.62$2.62$2.62
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25351--9
Nov, 25441--9
Oct, 25441--9
Sep, 25441--9
Aug, 25441--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 14, 2024Etzer DaroutBMO Capital$27.00$7.92240.91%930.53%
Sep 16, 2024Etzer DaroutBMO Capital$28.00$8.91214.25%968.70%
Aug 13, 2024Matthew BieglerOppenheimer$18.00$7.26147.93%587.02%
May 14, 2024Matthew BieglerOppenheimer$21.00$8.36151.20%701.53%
May 14, 2024Emily BodnarH.C. Wainwright$22.00$8.35163.47%739.69%
May 14, 2024Etzer DaroutBMO Capital$25.00$8.51193.77%854.20%
Apr 25, 2024Joseph CatanzaroPiper Sandler$30.00$9.20226.09%1045.04%
Apr 25, 2024Silvan TuerkcanJMP Securities$17.00$9.5078.95%548.85%
Mar 28, 2024Emily BodnarH.C. Wainwright$20.00$7.19178.16%663.36%
Dec 12, 2022Jefferies$17.00$12.5036.00%548.85%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 31, 2025Cantor FitzgeraldOverweightinitialise
Nov 14, 2024BMO CapitalOutperformOutperformhold
Sep 16, 2024Cowen & Co.BuyBuyhold
Sep 16, 2024Piper SandlerOverweightOverweighthold
Sep 16, 2024BMO CapitalOutperformOutperformhold
Sep 16, 2024H.C. WainwrightBuyBuyhold
Aug 14, 2024BMO CapitalOutperformOutperformhold
Aug 13, 2024OppenheimerOutperformOutperformhold
May 14, 2024OppenheimerOutperformOutperformhold
May 14, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.74$-0.24----
Avg Forecast$-2.62$-2.52$-2.82$-2.74$-2.25$-0.93
High Forecast$-2.50$-2.36$-2.22$-1.90$-0.90$-0.93
Low Forecast$-2.83$-2.72$-3.46$-3.51$-4.86$-0.93
Surprise %4.58%-90.48%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$716.11K$19.96M$79.99M$171.76M
High Forecast--$716.11K$19.96M$83.59M$171.76M
Low Forecast--$716.11K$19.96M$76.39M$171.76M
Surprise %------

Net Income Forecast

$-110M $-91M $-72M $-53M $-34M $-15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-60.39M$-80.56M----
Avg Forecast$-60.39M$-56.08M$-62.75M$-59.71M$-63.65M$-20.62M
High Forecast$-55.27M$-52.09M$-49.02M$-41.94M$-19.92M$-20.62M
Low Forecast$-62.54M$-60.07M$-76.47M$-77.49M$-107.37M$-20.62M
Surprise %-43.64%----

ACRV Forecast FAQ

Is Acrivon Therapeutics stock a buy?

Acrivon Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Acrivon Therapeutics is a favorable investment for most analysts.

What is Acrivon Therapeutics's price target?

Acrivon Therapeutics's price target, set by 10 Wall Street analysts, averages $21.83 over the next 12 months. The price target range spans from $17 at the low end to $30 at the high end, suggesting a potential 733.21% change from the previous closing price of $2.62.

How does Acrivon Therapeutics stock forecast compare to its benchmarks?

Acrivon Therapeutics's stock forecast shows a 733.21% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Acrivon Therapeutics over the past three months?

  • December 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 44.44% Strong Buy, 44.44% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 44.44% Strong Buy, 44.44% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Acrivon Therapeutics’s EPS forecast?

Acrivon Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.82, marking a 1075.00% increase from the reported $-0.24 in 2024. Estimates for the following years are $-2.74 in 2026, $-2.25 in 2027, and $-0.93 in 2028.

What is Acrivon Therapeutics’s revenue forecast?

Acrivon Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $716.11K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $19.96M, followed by $79.99M for 2027, and $171.76M for 2028.

What is Acrivon Therapeutics’s net income forecast?

Acrivon Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-62.745M, representing a -22.11% decrease from the reported $-80.556M in 2024. Projections indicate $-59.715M in 2026, $-63.645M in 2027, and $-20.621M in 2028.